Special Report: FDA's lax rules on coronavirus blood tests open U.S. market to dubious vendors
(Reuters) – As the coronavirus pandemic engulfed the United States, Joe Shia, a consultant to Chinese medical companies, said he was bombarded with inquiries from American firms who saw a golden opportunity in selling tests to determine coronavirus immunity. Unlike his typical clients, some firms